415 related articles for article (PubMed ID: 19773546)
21. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Hahn M; Li W; Yu C; Rahmani M; Dent P; Grant S
Mol Cancer Ther; 2005 Mar; 4(3):457-70. PubMed ID: 15767555
[TBL] [Abstract][Full Text] [Related]
23. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
24. Follicle-stimulating hormone regulates pro-apoptotic protein Bcl-2-interacting mediator of cell death-extra long (BimEL)-induced porcine granulosa cell apoptosis.
Wang XL; Wu Y; Tan LB; Tian Z; Liu JH; Zhu DS; Zeng SM
J Biol Chem; 2012 Mar; 287(13):10166-10177. PubMed ID: 22235114
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line.
Nuutinen U; Postila V; Mättö M; Eeva J; Ropponen A; Eray M; Riikonen P; Pelkonen J
Exp Cell Res; 2006 Feb; 312(3):322-30. PubMed ID: 16309671
[TBL] [Abstract][Full Text] [Related]
26. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Gillespie S; Borrow J; Zhang XD; Hersey P
Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
[TBL] [Abstract][Full Text] [Related]
28. Human intestinal epithelial crypt cell survival and death: Complex modulations of Bcl-2 homologs by Fak, PI3-K/Akt-1, MEK/Erk, and p38 signaling pathways.
Harnois C; Demers MJ; Bouchard V; Vallée K; Gagné D; Fujita N; Tsuruo T; Vézina A; Beaulieu JF; Côté A; Vachon PH
J Cell Physiol; 2004 Feb; 198(2):209-22. PubMed ID: 14603523
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Yu XD; Wang SY; Chen GA; Hou CM; Zhao M; Hong JA; Nguyen DM; Schrump DS
Cancer J; 2007; 13(2):105-13. PubMed ID: 17476138
[TBL] [Abstract][Full Text] [Related]
30. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
31. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
32. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
33. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
34. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
Pei XY; Dai Y; Felthousen J; Chen S; Takabatake Y; Zhou L; Youssefian LE; Sanderson MW; Bodie WW; Kramer LB; Orlowski RZ; Grant S
PLoS One; 2014; 9(3):e89064. PubMed ID: 24594907
[TBL] [Abstract][Full Text] [Related]
35. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
[TBL] [Abstract][Full Text] [Related]
36. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
37. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.
Wickenden JA; Jin H; Johnson M; Gillings AS; Newson C; Austin M; Chell SD; Balmanno K; Pritchard CA; Cook SJ
Oncogene; 2008 Dec; 27(57):7150-61. PubMed ID: 18806830
[TBL] [Abstract][Full Text] [Related]
38. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
Chen C; Chang YC; Lan MS; Breslin M
Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
[TBL] [Abstract][Full Text] [Related]
39. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
[TBL] [Abstract][Full Text] [Related]
40. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
